SGEN - Seattle Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Seattle Genetics, Inc.

21823 30th Drive SE
Bothell, WA 98021
United States
425-527-4000
http://www.seattlegenetics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees1,100

Key Executives

NameTitlePayExercisedAge
Dr. Clay B. SiegallCo-Founder, Chairman, Pres & CEO1.86M8.7M56
Mr. Todd E. SimpsonCFO & Principal Accounting Officer757.28kN/A56
Dr. Vaughn B. Himes Ph.D.Chief Technology Officer700.44k2.41M56
Dr. Jonathan G. Drachman M.D.Chief Medical Officer and Exec. VP of R&D817.17k720.86k55
Ms. Jean I. Liu J.D., M.S.Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec.N/AN/A49
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

Corporate Governance

Seattle Genetics, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 4. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.